 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol IDs
|
|
|
| |
Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma
|
|
|
|
Phase III
|
|
|
|
EORTC-18021
EUDRACT-2004-002245-12, NCT00110123
|
|
| |
Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma
|
|
|
|
Phase III
|
|
|
|
NCI-06-C-0088
NCI-P6701, NCT00324727
|
|
| |
Lucentis as an Adjuvanct Therapy With TTT-ICG Based in Choroidal Melanoma
|
|
|
|
Phase III
|
|
|
|
FVF4290s
NCT00680225
|
|
| |
Calcitriol and Temozolomide in Treating Patients With Metastatic Melanoma
|
|
|
|
Phase II, Phase I
|
|
|
|
NU-05M1
NU-0310-093, SPRI-NU-05M1, NCT00301067
|
|
| |
Vaccine Therapy and Autologous Lymphocyte Infusion With or Without Fludarabine in Treating Patients With Metastatic Melanoma
|
|
|
|
Phase II, Phase I
|
|
|
|
MCC-13649
LAC-USC-10M-05-2, 6241, NCI-6241, LAC-USC-HS-05-00068, NCT00313508
|
|
| |
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
|
|
|
|
Phase II
|
|
|
|
MCC-15241
MDX-010-16, NCI-6446, 6446, NCT00084656, LAC-USC-10M036
|
|
| |
Lenalidomide in Treating Patients With Stage IV Eye Melanoma
|
|
|
|
Phase II
|
|
|
|
NCI-05-C-0095
NCI-P6501, NCT00112606
|
|
| |
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
|
|
|
|
Phase II
|
|
|
|
PMH-PHL-040
NCI-6916, 6916, NCT00121225
|
|
| |
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
|
|
|
|
Phase II
|
|
|
|
PMH-PHL-038
7137, NCT00243061
|
|
| |
Taxoprexin® Treatment for Advanced Eye Melanoma
|
|
|
|
Phase II
|
|
|
|
P01-04-22
NCT00244816
|
|
